Thin Endometrium and ACT: A Fertility Patient's Guide to Endometrial Regeneration | ALIV

An endometrial lining below 7mm on the day of embryo transfer significantly reduces implantation rates — even when the embryo is of excellent quality. For women with refractory thin endometrium — where the standard interventions of oestrogen therapy, sildenafil, aspirin, and endometrial scratching have failed to achieve adequate thickness — the options in conventional fertility medicine are extremely limited. ALIV's ACT programme for thin endometrium, led by Dr. Sunita Tandulwadkar, applies autologous growth factors to support endometrial regeneration in women for whom standard approaches have been exhausted.

Why Thin Endometrium Is Difficult to Treat

Thin endometrium typically results from one of several mechanisms: reduced endometrial blood flow (often from intrauterine adhesions, prior uterine surgery, or vasculopathy); insufficient oestrogen receptor expression in the endometrium; or primary endometrial glandular insufficiency where the glandular epithelium is unable to proliferate adequately regardless of hormonal stimulation. Standard treatments (high-dose oestrogen, vasodilators) address blood flow and hormonal stimulation — they do not address primary glandular insufficiency or the fibrotic endometrium left after Asherman's syndrome surgery. This is the gap ACT addresses: growth factor support (VEGF for endometrial angiogenesis; EGF and IGF-1 for endometrial glandular proliferation) delivered directly to the endometrial tissue to stimulate the proliferative response that hormonal therapy has been unable to achieve.

The Clinical Protocol

ALIV's thin endometrium ACT protocol involves administration of the processed autologous preparation via the intrauterine route — delivered through a soft catheter into the uterine cavity under ultrasound guidance, in a procedure analogous to intrauterine insemination (IUI). The delivery is to the endometrial surface directly, allowing the growth factors to be taken up by the endometrial stroma and glandular cells. This is performed in the proliferative phase of the cycle — typically cycle days 7–10 — to align with the natural oestrogen-driven proliferative window and provide the growth factor support during the period when the endometrium is most responsive to proliferative stimuli. Serial endometrial thickness monitoring by transvaginal ultrasound tracks the response over the three to four weeks following the procedure.

How quickly does endometrial thickness respond to ACT?

When a response occurs, endometrial thickness improvement is typically observable on the first ultrasound following the procedure — within four to ten days. Some patients achieve adequate thickness for embryo transfer in the same cycle as the ACT procedure; others require one to two additional cycles for the response to be established. Response varies significantly — patients with primary fibrotic endometrium (post-Asherman's) typically respond more slowly and less dramatically than patients with thin endometrium from vasculopathy, where the growth factor angiogenic effect can produce relatively rapid thickness improvement. Dr. Tandulwadkar's pre-procedure assessment classifies the likely mechanism and provides the most appropriate individual prognosis.

Can ACT be combined with frozen embryo transfer (FET)?

Yes — and this is the typical clinical sequence for thin endometrium patients who have frozen embryos available. ACT is performed to achieve adequate endometrial thickness; once the threshold is achieved and maintained, FET is scheduled in the subsequent cycle under optimal endometrial preparation. ALIV coordinates the ACT and FET timing with the patient's IVF clinic to ensure the embryo transfer proceeds at the optimal endometrial window after ACT-supported regeneration.